Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Year Ahead In Europe: More Price Cuts, More Austerity

Executive Summary

Further austerity plans will be drawn up and drug price cuts implemented in Europe during 2012, as governments try to come to grips with their debts and with the eurozone currency crisis.


Related Content

Italian Rx Price Cuts Are Brand Pharma’s Pain; Will They Even Be Generics’ Gain?
European Regulatory Round-Up: EMA And The UK Heed The Calls Of Industry; France Is Otherwise Occupied
European Regulatory Round Up: While EMA Opens Up, European Pharma Battens Down For Tough Year
Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
Intermune’s Esbriet Flops In Front Of IQWiG
French Pharma Industry Pays The Price For Country’s Financial Woes
Rx Class Action Suits May Come To France In Response To Mediator Scandal
Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment
With Its Economy Struggling, Spain Launches Second Cost-Cutting Exercise In Two Years
UK Value-Based Pricing Proposals Aim To Increase Access, Broaden Assessment of Drug Benefits


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts